520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway
| Autor: | Meijun Wang, Fen Xu, Riying Liang, Mengyin Cai |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Kidney
medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism medicine.medical_treatment Intraperitoneal injection Type 2 diabetes medicine.disease medicine.anatomical_structure Endocrinology Insulin resistance Downregulation and upregulation Apoptosis Internal medicine Internal Medicine Medicine business Exenatide TXNIP medicine.drug |
| Zdroj: | Diabetes. 69 |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/db20-520-p |
| Popis: | Recent studies have indicated apoptosis to be a major contributor to the progression of Diabetic Kidney Disease. GLP-1 agonist such as Exenatide, which counteracts insulin resistance in humans with type 2 diabetes, has been shown to ameliorate Diabetic Kidney Disease in experimental models. In this study, we investigated whether exenatide could alleviate Diabetic Kidney Disease by apoptosis through SIRT1/TXNIP signal pathway. Male C57BL/6J mice challenged with a high-fat diet (HFD) for 12weeks were then treated with exenatide (HFD+exe) or normal saline(HFD+sal) by intraperitoneal injection for 8 weeks. The results revealed that Exenatide notably decreased body weight, urine albumin-to-creatinine ratio(ACR) and apoptosis in the kidney induced by HFD challenge. Western blot revealed the level of apoptosis were notably downregulated after exenatide treatment. In addition, the protein expression of SIRT1 was upregulated, whereas TXNIP was downregulated in the HFD+exe group. Collectively, the data indicate that Exenatide ameliorates Diabetic Kidney Disease by inhibiting apoptosis via SIRT1/TXNIP signal pathway. Disclosure M. Wang: None. R. Liang: None. F. Xu: None. M. Cai: None. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|